Abstract Objective: The common femoral artery (CFA) is an unusual location for endovascular repair (ER). We report the early results after ER of the CFA in a single centre. Design: This is a cohort study. Materials/Methods: From 2006 to 2008, ER of the CFA was proposed to 36 patients (mean age 67.9, range 51e92). CFA lesions were classified into four types: in type I, lesions were located at the iliac external artery and were extended to the CFA; in type II, lesions were limited to the CFA; in type III, lesions were located at the CFA and its bifurcation; type IV represents restenosis bypass anastomosis. All patients were treated by stenting. Results: Indications for ER of the CFA included 25 patients (70%) for claudication and 11 patients (30%) for critical limb ischaemia. Forty-three stents were implanted. The mean follow-up was 22 months (range, 12e42). At 1 year, primary and secondary sustained clinical improvements were 80% and 90%; target lesion revascularisation and target extremity revascularisation free cumulative survival were 85% and 80%, respectively, and in-stent restenosis rate was 20%. One stent fracture was noted. Conclusions: ER of CFA and concomitant arterial lesions seems to be a safe technique with acceptable clinical outcome at 1 year. ª
Over the past years, endovascular interventions have become an important part of treatment in patients with peripheral arterial disease. 1 Even though the indication for endovascular therapy has been enlarged, open repair of common femoral artery (CFA) is still considered as the treatment of choice. Recent studies confirm its safety and its efficacy. 2e4 Treatment of CFA by endovascular therapy is avoided in this highly mobile area because of the risk of stent fracture and because it compromises future surgical options, 5, 6 but is also based on the good results of open repair.
However, the evidence to support open repair as the standard treatment of CFA disease is not so obvious. First, studies have reported high rates of perioperative complications following CFA endarterectomy. 2, 3 In 2001, Cardon et al. reported a local morbidity rate of 21.6% after common femoral endarterectomy with 18% of minor complications and 3.6% of complications requiring a second operation. More recently, Kang et al. noted 5% of major complications requiring re-intervention and 9% of minor complications, which were treated conservatively. All these studies were retrospective and complications, such as postoperative dysaesthesia, were underestimated. Second, analysis of the anatomical behaviour of CFA during movements shows that CFA is a relatively fixed artery between the inguinal ligament above and the Sartorius muscle below. 7 Third, newer generations of nitinol stent could expand endovascular treatment for periarticular locations thanks to their resistance to compression and fracture in the tortuous physical environment. 5, 8 Few data are available on the treatment of CFA by emerging endovascular techniques. 9, 10 Herein, we report the early outcomes of CFA primary stenting.
Materials and Methods

Experimental design/setting
From June 2006 to October 2008, endovascular therapy was considered for CFA occlusive disease. All patients received oral and written information about the procedure and the lack of an existing long-term efficacy study. Inclusion criteria included intermittent claudication or critical ischaemia due to atherosclerotic disease (Rutherford stages 2e5), and a haemodynamically significant lesion (diameter reduction of >70% detected by duplex scan and confirmed by computed tomography (CT) scan or magnetic resonance (MR) imaging). Patients with CFA thrombosis were excluded. Patients with claudication underwent conservative therapy for 3e6 months before surgical procedure. Each patient may have either one or both limbs treated in the study.
The endovascular technique was proposed as a first-line treatment in all patients. The first endovascular cases were high-risk patients with severe co-morbidities (classified as type 3 and 4 according to the American Society of Anesthesiologists score) with claudication or critical limb ischaemia. During the last months of the series, with an increase in expertise and confidence, the endovascular repair was proposed for all patients as a first-line treatment.
CFA occlusive disease classification ( Fig. 1) Based on findings by Lopez et al 7 and patient medical history, we classified CFA occlusive lesions into four groups. Type I represents lesions that are located at the iliac external artery and are extended to the CFA. In type II, lesions are limited to the CFA. Type III represents lesions that are located at the CFA and its bifurcation. Finally, type IV represents proximal or distal stenosis bypass anastomoses.
Endovascular procedures
All procedures were performed in the operating room by vascular surgeons. Anaesthesiologists examined all patients preoperatively. Local anaesthesia with conscious sedation was indicated, unless general anaesthesia was needed in patients who were restless and in pain. Access to the culprit lesion was achieved either by way of an over-the-aortic bifurcation approach with the use of a dedicated 6-F or 7-Flong sheath (45 cm) (Destination Ò , Terumo, St Quentin en Yvelines, France) or via a brachial approach with the use of a dedicated 6-F or 7-F-long sheath (90 cm) (Destination Ò , Terumo). After sheath placement, an intravenous bolus of 50 UI kg À1 of heparin was given. Digital subtraction angiography (DSA) was performed to assess lesions. After successful passage of the target lesions with a hydrophilic 0.035-inch guide wire, primary stenting without lesion predilatation was preferably performed. In type III lesions, balloon-expandable stents were used to treat ostial stenoses of superficial and deep femoral arteries. In type III lesions, the superficial femoral artery (SFA) was abandoned if it was occluded at the origin, with a stent placed from the CFA into the profunda femoral artery. In tight stenosis that precluded stent advancement, angioplasty with a 3-mm balloon was done to allow stent placement. The stent dimensions were chosen such that the nominal diameter was equal to the reference vessel diameter and the length exceeded the lesion length by 5e10 mm proximal and distal. Vessel sizes were determined on the basis of preoperative CT scan or MR imaging. The intention was to cover the lesion with a single stent. 11 and the length did not exceed the stent length. The technical result of the procedure was assessed by DSA.
Groin and brachial closure was accomplished via manual compression. In some cases, a vascular closure device (Angioseal Ò , St Jude Medical, Issy Les Moulineaux) was used to seal the femoral artery puncture.
A prophylactic dose of low-molecular-weight heparin was given during the duration of hospitalisation to prevent venous thrombo-embolic events. Postoperatively, patients were prescribed aspirin (75e160 mg day À1 ) and clopidogrel (75 mg day À1 ) for 6 months. After 6 months, patients were prescribed only clopidogrel (75 mg day À1 ). 
Follow-up
Postoperatively, patients were prospectively followed-up on an outpatient basis. Major adverse clinical events (MACE) were intentionally sought. Follow-up included clinical, duplex ultrasound examinations and biplane X-ray at 1, 6 and 12 months and yearly thereafter. Patient data, imaging parameters, intraoperative data and postoperative events were recorded prospectively in a computerised database.
End points and definitions
The main end point was primary sustained clinical improvement. Secondary end points were procedural success, secondary sustained clinical improvement, MACE, primary patency, target lesion revascularisation (TLR), target extremity revascularisation (TER), in-stent restenosis and stent fracture. Detailed definitions of outcome are as follows: Primary sustained clinical improvement was defined as a sustained upward shift of !1 category of the Rutherford classification without the need for repeated TLR in surviving patients. Secondary sustained clinical improvement was defined as a sustained upward shift of !1 category of the Rutherford classification including the need for repeated TLR in surviving patients. MACE included all deaths, major amputation, procedural-related serious adverse events and device failure or malfunction. TLR expresses the frequency of the need for repeated procedures (endovascular or surgical) due to a problem arising from the lesion initially treated (þ1 cm proximally and distally to include edge phenomena) in surviving patients with preserved limb. TER expresses the frequency of the need for repeated procedures (endovascular or surgical) due to a problem arising remote from the lesion initially treated in surviving patients with preserved limb. 15 Procedural success was defined by the ability to cross the lesion with the guide wire and to inflate the artery with a stent. Primary patency was defined as patency without any percutaneous or surgical intervention in the CFA or in the adjacent areas. Patency and in-stent restenosis were assessed by duplex ultrasound. In-restenosis was defined by restenosis of >50% and by a peak systolic velocity index >2.4 at the target lesion. 16 Patients were defined as lost to follow-up when no further follow-up studies were available beyond a particular completed follow-up interval. The occurrence of stent fracture was determined by biplane radiography at 1, 6 and 12 months. Stent fractures were classified according to the Jaff et al. classification. 17 
Statistical analysis
Statistical analysis results were reported prospectively on an intent-to-treat basis and analysed. Continuous variables were presented as mean AE SD, categorical variables as count and percent. Demographic and co-morbidity data were recorded per patient and patency data were calculated on a per limb basis. Survival rate curves for TLR/TER were plotted and calculated using the KaplaneMeier method. The time occurrence of events (TER/TLR) was analysed with a univariate Cox proportional-hazards model to assess the specific effect of each predictor. Predictive factors included age, sex, presence or absence of diabetes, stage of peripheral artery disease, types of CFA lesions, types of stents (balloon-expendable and self-expandable stents), The InterSociety Consensus for Management of PAD (TASC) status and runoff. In patients who died before the final follow-up examination or in patients lost to follow-up, we have taken account of the status of the last follow-up examination. Instent restenosis at 12 months was analysed with univariate logistic models. A p < 0.05 was considered statistically significant. Data were analysed using the Statistical Package for Social Sciences (SPSS) (SPSS Inc., Chicago, IL, USA).
Results
Patients' characteristics and demographics ( Intraoperative data (Tables 2 and 3) Classification of the lesions is summarised in Table 2 . For type IV lesions, two proximal and three distal stenosis bypass anastomoses were treated. Local anaesthesia was used in 33 patients (91.6%). Procedural success was 100%. No dissection or arterial rupture was observed. No open surgery for conversion was required. The over-the-bifurcation approach was used to treat 27 CFA (67.5%). Nine CFA were treated by a brachial approach. The brachial approach was performed because of obesity, previous aortobifemoral bypass and aortic endograft. In four cases, an ipsilateral approach was chosen via the CFA for type 1 lesions or via the SFA for type 2 lesions. When the SFA was the vessel accessed, the puncture was performed at the first centimetres of the SFA and a femoral closure device was used to prevent bleeding or pseudoaneurysm. Predilatation was performed for five limbs (12.5%). Forty-three stents were implanted and four types of commercially available stents were used: Amiia Ò (Cordis), Everflex Ò (EV3), E-Luminexx (Bard) and Flexstar Ò (Bard). Mainly self-expandable stents were used (88.3%). Balloonexpandable stents were chosen to treat five lesions of type III. In one patient, a femoro-poplitaeal bypass was associated with a type I lesion. Concomitant endovascular treatment was performed in 24 cases (60%): in 15 cases to improve inflow and in nine cases to improve outflow (Table 3) .
Perioperative data
No patient was lost to follow-up. No patient required intensive unit care. The perioperative morbid-mortality rate was 5% (n Z 2). One patient required re-intervention for a haematoma at the femoral puncture site after an over-the-bifurcation approach. One patient required a major amputation. This patient presented a critical limb ischaemia with extensive lesion to the foot. No distal revascularisation was possible. CFA stenting was done prior to a transtibial amputation. The patient went on to recover from the transtibial amputation. The mean length of hospital stay was 2.9 days (range 1e15 days). The median length of hospital stay was 2 days. Three patients were hospitalised in the context of day-case vascular procedure. In these cases, an arterial femoral closure device (Angioseal Ò 6F, St Jude Medical) was used to allow early discharge. Other patients were hospitalised for 2 days 
Follow-up
Complete follow-up data were obtained for all limbs at 12 months. Mean follow-up was 22 months. At 6 months of follow-up, both primary and secondary sustained clinical improvements were 90%. At 12 months of follow-up, primary and secondary sustained clinical improvement were 80% and 90%, respectively. During this study, one stent fracture was noted at 6 months based on X-ray interpretation. The stent fracture was classified as a type 3 and occurred in a patient treated by a nitinol stent for a type I CFA lesion (Fig. 2) . This fracture was associated with in-stent restenosis within 12 months.
At 12 months, we observed eight cases of in-stent restenosis (20%). In four cases, restenosis was not critical and the patients were still asymptomatic. Therefore, no reintervention was performed. In two cases, endovascular procedures were required to treat in-stent restenosis by balloon angioplasty. In two other cases, open procedures were preferred to treat in-stent restenosis because of severe aorto-iliac atherosclerotic lesions, which had probably been underestimated. With a univariate logistic model, any risk factors (age, sex, diabetes, stage of peripheral artery disease, types of CFA lesions, types of stents, TASC status and runoff) were not significantly associated with in-stent restenosis at 12 months.
TLR-and TER-free cumulative survival are represented in Figs. 3 and 4 . At 1 year, TLR-and TER-free cumulative survival were 85% and 80%, respectively. At 6 months, one patient underwent open redo procedure (aortobifemoral and femoro-tibial bypasses) and two patients underwent a venous femoro-poplitaeal bypass between the profunda femoris artery and the below-knee poplitaeal artery. Between 6 and 12 months, three other patients underwent redo procedures. CFA angioplasty was performed for instent restenosis in two patients and aortofemoral bypass was performed in the other case. With univariate Cox analysis, only age was a significant predictor (p Z 0.05) of a TLR event. There were no significant predictors of a TER event.
Discussion
Over the perioperative period, this study has shown that endovascular repair of the CFA and concomitant arterial lesions are feasible and safe procedures. At 12 months, the sustained clinical improvements were acceptable even if the occurrence of in-stent restenosis should be taken into account. This study has some limitations. Even though this study is prospective, there is no control group and no randomisation. Patients were included at the discretion of the surgeon, the number of interventions is relatively small and the patient group is heterogeneous. Indeed, we have mixed intermittent claudication and critical ischaemia. The follow-up is short. Finally, a subjective clinical scale was used for the primary end point evaluation and the ankleebrachial index or treadmill exercise testing was not systematically performed to objectively evaluate patients' outcomes. Regarding statistical analysis, multivariable assessment in Cox models was not powered to individuate independent predictors.
To our knowledge, we propose here the first classification of CFA atherosclerotic disease. This classification in four types is based on the findings of Lopez. 7 In 1989, Lopez et al. studied the anatomical behaviour of the CFA when the hip joint passes from the position of extension to the position of flexion at 90 , using several methods such as anatomic sections, arteriography or vascular casts. During flexion of the hip joint, the CFA undergoes a movement of combined torsion on its axis and flexion at two different points on its course: the inguinal ligament above, representing the lower limit of the external oblique muscle, and the Sartorius muscle below. These two points divide the CFA into three parts that represent the first types. Type 4 represents stenotic bypass anastomoses. This type of lesion is particular as the stenosis is due to intimal hyperplasia.
In 2004, Stricker reported the results of a retrospective study regarding the stent-assisted angioplasty at the level of the CFA. 10 In this study 33 limbs were treated. At 3 years, 83% of the arteries were patent and five restenosis were observed. According to Stricker, the risk of in-stent restenosis could be higher for bypass anastomoses (type IV lesions).
The main reasons to choose endovascular repair rather than open repair for treating CFA is related to the advantages of mini-invasive procedures and the possibility to treat all the lesions by an endovascular technique. In one case, endovascular repair was performed in a patient undergoing concomitant distal bypass with the groin already exposed. In this case, CFA lesions were preoperatively underestimated and its repair was not scheduled. Hospital length of stay and perioperative morbidity are both reflective of the less invasive procedure. In our series, average hospital stay was 2.9 days. In comparison, Kang reported an average hospital stay of 3.2 days for open CFA procedures. 3 Factors such as local anaesthesia, percutaneous approach and use of arterial closure device could allow a shorter hospital length of stay in favour of the endovascular procedure. Similarly, endovascular treatment is considered to decrease the rate of perioperative morbidity. Our study reports a perioperative morbid-mortality rate of 5%. In Cardon's study, 2 the local morbidity rate was 21.6% with 18% of minor complications (haematoma and lymph link) and 3.6% of complications requiring a re-intervention. More recently, Kang reported 13.8% of complications after CFA endarterectomy and Ballotta noted 0% of major complications and 6.6% of local complications. 3, 18 These studies were retrospective and complications, such as postoperative dysaesthesia, were probably underestimated. With respect to the second issue, CFA endovascular repair could be performed to obtain a "total endovascular look." We showed that, in over half of the cases, CFA stenting was combined with an inflow or outflow ipsilateral endovascular procedure. Kang et al. have reported a similar rate by performing 57% of hybrid procedures during CFA endarterectomy. 3 On the other hand, isolated lesions of CFA (type II lesions) e though uncommon e are frequently associated with disabling peripheral ischaemic symptoms. In our study, 42.5% of the lesions were type 2 lesions, and indications for repair were claudication in 76% and critical limb ischaemia in 24%. In comparison, Mukherjee and Springhorn et al. reported open repair for isolated atherosclerotic lesions of the CFA for symptoms of critical limb ischaemia in 41% and 69%, respectively. 19, 20 More recently, Ballota reported that claudication was the indication for surgery in 60% and critical limb ischaemia in 40% of the patients undergoing CFA endarterectomy. 18 One serious consideration is that stenting of the CFA may complicate further open surgical procedures. In this study, two patients underwent extremity revascularisation procedures by venous femoro-poplitaeal bypass at 6 months. Because of the absence of in-stent restenosis at the CFA level, venous bypasses were performed between the profunda femoris artery and the below-knee popliteal artery. In case of in-stent restenosis, the CFA stent should be removed by performing a CFA endarterectomy. Endovascular repair of CFA may result in compromising the flow to the profunda femoris artery. For this reason, in type II and III lesions, we recommend to first catheterise the profunda femoris artery and to keep a guide into this artery during the entire procedure. Concerns of this technique are also related to the risk of stent fracture and the loss of the femoral approach for further percutaneous procedures. For certain clinicians, CFA stenting precludes further endovascular interventions at the puncture site. However, the CFA could be punctured under either fluoroscopic guidance or duplex scan just above or below the stent to prevent strut damage but increasing the risk of bleeding or pseudoaneurysms. Second, different approaches using radial, brachial or ipsilateral SFAs could be used. Regarding the risk of stent fracture, effects of joint motion on the structural Figure 4 Target extremity revascularisation-free cumulative survival.
integrity of periarticular stents are a concern to perform endovascular therapy. Indeed, stent fractures occur mostly in the bending vascular segments close to joints, such as femoro-popliteal and femoral segments. 21 In this study, we have reported one case of stent fracture. The fracture occurred above the inguinal ligament. Interestingly, this location was defined by Lopez as a point of flexibility where the artery undergoes a movement of combined torsion on its axis and flexion. 7 At 12 months, the CFA in-stent restenosis rate was 20%. Even though there was no significant correlation between the occurrence of in-stent restenosis and any adjusted factors, in-stent restenosis seemed particularly frequent with type III lesions. In this case, stents are implanted just in front of the Sartorius muscle. Consequently, the Sartorius muscle could alter the structural integrity of the stent and the arterial wall.
In conclusion, endovascular repair of the CFA seems to be a safe technique of revascularisation, with acceptable initial results at 12 months. However, endovascular repair of the CFA mandates ongoing surveillance and longer follow-up, given the great mobility of the hip joint and the dynamic modification of the femoral artery. Thanks to this pilot study, a French randomised and controlled trial has been set up to compare open and endovascular procedures for the treatment of CFA atherosclerotic lesions. This trial has obtained a secured financial support from the National French Grant PHRC.
